RAPYDAN

This brand name is authorized in Austria, Ireland, Netherlands, Poland

Active ingredients

The drug RAPYDAN contains a combination of these active pharmaceutical ingredients (APIs):

1 Lidocaine UNII 98PI200987 - LIDOCAINE

Lidocaine, like other local anaesthetics, causes a reversible blockade of impulse propagation along nerve fibres by preventing the inward movement of sodium ions through the nerve membrane. Local anaesthetics of the amide-type are thought to act within the sodium channels of the nerve membrane. Read about Lidocaine

2 Tetracaine UNII 0619F35CGV - TETRACAINE

Tetracaine is a local anaesthetic and is believed to act by blocking nerve conduction mainly by inhibiting sodium ion flux across the axon membrane. Read about Tetracaine

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code	Group title	Classification
N01BB52	Lidocaine, combinations	N Nervous system → N01 Anesthetics → N01B Anesthetics, local → N01BB Amides
Discover more medicines within N01BB52

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
Country: NL	Z-Index G-Standaard, PRK	Identifier(s): 85456
Country: PL	Rejestru Produktów Leczniczych	Identifier(s): 100196796